Get the Stockscreener App
358.35
0.05%
-0.18
After Hours:
358.35
United Therapeutics Corp stock is traded at $358.35, with a volume of 261.54K.
It is down -0.05% in the last 24 hours and down -1.43% over the past month.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
See More
Previous Close:
$358.53
Open:
$358.62
24h Volume:
261.54K
Relative Volume:
0.60
Market Cap:
$15.94B
Revenue:
$2.62B
Net Income/Loss:
$1.07B
P/E Ratio:
19.74
EPS:
18.15
Net Cash Flow:
$877.90M
1W Performance:
+0.78%
1M Performance:
-1.43%
6M Performance:
+55.99%
1Y Performance:
+58.65%
1-Day Range:
$352.93
$360.63
1-Week Range:
$347.00
$362.52
52-Week Range:
$208.62
$366.08
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Industry
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Grows Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Manchester gets offer from United Therapeutics to buy nearly 350 acres in Hackett Hill area - AOL
Manchester gets offer from United Therapeutics to buy nearly 350 acres in Hackett Hill area - The Union Leader
Liquidia Moves Again to Block FDA Exclusivity of UTC Lung Drug - Bloomberg Law
United Therapeutics CFO sells over $2.3m in company stock By Investing.com - Investing.com Australia
United Therapeutics CFO sells over $2.3m in company stock By Investing.com - Investing.com South Africa
United Therapeutics CFO sells over $2.3m in company stock By Investing.com - Investing.com Canada
United Therapeutics CFO sells over $2.3m in company stock - Investing.com
United Therapeutics (NASDAQ:UTHR) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting - StockTitan
United Therapeutics stock target raised significantly as Tyvaso shows promise in cardiopulmonary market - Investing.com Canada
Jefferies Financial Group Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $432.00 - MarketBeat
Tri Locum Partners LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics stock target raised significantly as Tyvaso shows promise in cardiopulmonary market - Investing.com
Pacer Advisors Inc. Buys 92,240 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (UTHR) Is Thriving on Strong Demand and Smart Pricing - Insider Monkey
United Therapeutics (UTHR) Is Thriving on Strong Demand and Smart Pricing - Yahoo Finance
United Therapeutics Co. (NASDAQ:UTHR) Receives $350.36 Consensus Target Price from Analysts - MarketBeat
Waterloo Capital L.P. Decreases Stake in Ulta Beauty, Inc. (NASDAQ:ULTA) - Defense World
Inspire Investing LLC Buys 2,936 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Uxin (UXIN) Scheduled to Post Earnings on Monday - Defense World
Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment - Seeking Alpha
Parallel Advisors LLC Raises Position in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Oppenheimer Asset Management Inc. Grows Stock Position in Ulta Beauty, Inc. (NASDAQ:ULTA) - Defense World
Ultimate Products Completes Share Buyback - TipRanks
E Fund Management Co. Ltd. Buys 2,125 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Oppenheimer & Co. Inc. Acquires 530 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World
1,054 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Choreo LLC - Defense World
Quest Partners LLC Has $89,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Ultra Clean Holdings, Inc. (NASDAQ:UCTT) Holdings Cut by Victory Capital Management Inc. - Defense World
Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com Canada
Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com Australia
Ultimate Products Advances Share Buyback Plan - TipRanks
Liquidia Corp faces renewed legal challenge from United Therapeutics - Investing.com India
Liquidia Corp faces renewed legal challenge from United Therapeutics - Investing.com
Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com South Africa
Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com UK
United Therapeutics swells North Carolina footprint with $33M deal - The Business Journals
Urban Outfitters, Inc. (NASDAQ:URBN) Stock Holdings Lifted by Texas Permanent School Fund Corp - Defense World
Ultimate Products Advances Share Buyback Program - TipRanks
Court rules against United Therapeutics in Liquidia case - Investing.com
Unum Group stock outperforms competitors on strong trading day - MarketWatch
North Carolina Powerhouse: Smith Anderson - Law360
Universe Pharmaceuticals INC (UPC) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million - Yahoo Finance
Investing in Universe Pharmaceuticals INC (UPC) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
694 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Caprock Group LLC - Defense World
UTime to sell 7.69M shares at 65c in registered direct offering - TipRanks
Sandoz Awarded $137M In Generic Hypertension Drug Fight - Law360
UTHRUnited Therapeutics Corp Latest Stock News & Market Updates - StockTitan
Andra AP fonden Increases Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):